SCHEMBL206426

SCHEMBL206426

Fc1ccc2nc(Nc3nc(-c4cccnc4)cs3)sc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.66
MEN1 O00255 9/20 0.64
KMT2A Q03164 9/20 0.64
RAB9A P51151 8/20 0.64
MAPT P10636 6/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
CYP1A1 P04798 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP1B1 Q16678 1/20 0.58
MCL1 Q07820 1/20 0.57
MAPK1 P28482 1/20 0.56
NPC1 O15118 8/20 0.52
GAA P10253 3/20 0.52
PKM P14618 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
LMNA P02545 1/20 0.52
VCP P55072 1/20 0.52
TP53 P04637 1/20 0.52
ALDH1A1 P00352 2/20 0.52
CASP3 P42574 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207484 0.87 GAA (0.65) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL206828 0.81 RAB9A (0.51) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL7679868 0.80 MAPK1 (0.82) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL19839869 0.79 RAB9A (0.70) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL18083891 0.78 MEN1 (1.00) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL206917 0.78 NPC1 (0.61) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL14059092 0.75 RAB9A (0.78) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL250600 0.74 RAB9A (0.64) MEN1KMT2ARAB9AMAPTSMN1; SMN2
SCHEMBL206743 0.74 MEN1 (0.80) MEN1KMT2ARAB9AMAPTSMN1; SMN2
Bromide SCHEMBL14054264 0.74 RAB9A (0.76) MEN1KMT2ARAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 SLC2A1 165/4885MEN1 3862/4885KMT2A 3476/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 SLC2A1 165/4885MEN1 3862/4885KMT2A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.